Product Name:2-(6-Chloropyridazin-3-yl)-2-phenylacetonitrile

IUPAC Name:2-(6-chloropyridazin-3-yl)-2-phenylacetonitrile

CAS:73535-73-6
Molecular Formula:C12H8ClN3
Purity:95%
Catalog Number:CM275205
Molecular Weight:229.67

Packing Unit Available Stock Price($) Quantity
CM275205-250mg in stock ǵǵ
CM275205-1g in stock ŹǤĽ
CM275205-5g in stock ƓǤȎ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:73535-73-6
Molecular Formula:C12H8ClN3
Melting Point:-
Smiles Code:N#CC(C1=NN=C(Cl)C=C1)C2=CC=CC=C2
Density:
Catalog Number:CM275205
Molecular Weight:229.67
Boiling Point:
MDL No:
Storage:

Category Infos

Pyridazines
Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

Column Infos

Neflamapimod
Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.

Related Products